2026 Q1 -tulosraportti
Äänite tulossa
2 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·10 t sittenClipped from TI: They sign confidentiality agreements (CDA/NDA) and gain access to "data rooms" When a potential partner shows interest (as we know from the Q1/Q3 reports that SoftOx is already in dialogue with), they sign a legally binding confidentiality agreement (Confidential Disclosure Agreement). Once it is signed, Big Pharma gains access to SoftOx's virtual "data room". Here they get access to extremely detailed information that is not publicly known: Raw data from previous safety studies, exact design of the CF study, animal studies (in vivo/in vitro), and patents in detail. With the recent appointment of Dr. Tore Duvold to the board – a man with extensive industrial experience from licensing agreements – it is overwhelmingly probable that the process is already underway Either a player can position itself now with a licensing agreement during 2026 to secure the rights before competitors. The price tag will be lower because BP still takes some of the clinical risk towards H1 2027. Alternatively, they can await the outcome in 2027. If the data from the Copenhagen study then shows a clear reduction in bacterial load, the medical risk is eliminated – but then SoftOx will probably be subject to an aggressive bidding war between several of the largest pharmaceutical giants, and the price tag for an acquisition will reflect the enormous global market potential.
·11 t sittenSeems like the market doesn't care much about that type of news anymore. Saw the same in Circio yesterday and in Lifecare a few days ago. At Lifecare, it actually went up 10-15 % before it crashed down again.
can one compare apples and bananas..? I Think not..that being said! then one should probably not put too much into one's expectations about what should happen with stocks, when there are "positive" news..we need more data. 📈 🚀- ·12 t sitten · MuokattuPositive message regarding the confirmation that no significant side effects were registered. But no data regarding effect as this study was with healthy volunteers. Efficacy data for SIS-03 will come in H1 2027 and with convincing data here, the stock price can really take off and go 10x or more. So this is a somewhat long-term case where one must exercise some patience. Without knowing for sure, there might be some news from SIS-02 during the autumn that could affect the stock price.
·12 t sittenWe must wait until next year for further news on whether the medicine combats the disease to some extent. In that case, we will make a lot of money, if not, we will lose, some less, some more.For me, it's nothing special, they talked about it earlier, secondly, I believe there will be a big reaction after any positive news about the substance's effectiveness, but we have to wait for that.
·12 t sitten · MuokattuThe proof is now in place showing that this is going smoothly towards PoC. My goodness, how low priced we are now and what a buying opportunity. Today's news should send us above 0,25We can't get above 0.12 and you're talking about over 100% increase. If a whale sees potential here, it would probably have hoovered up all the shares at this level?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Äänite tulossa
2 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenClipped from TI: They sign confidentiality agreements (CDA/NDA) and gain access to "data rooms" When a potential partner shows interest (as we know from the Q1/Q3 reports that SoftOx is already in dialogue with), they sign a legally binding confidentiality agreement (Confidential Disclosure Agreement). Once it is signed, Big Pharma gains access to SoftOx's virtual "data room". Here they get access to extremely detailed information that is not publicly known: Raw data from previous safety studies, exact design of the CF study, animal studies (in vivo/in vitro), and patents in detail. With the recent appointment of Dr. Tore Duvold to the board – a man with extensive industrial experience from licensing agreements – it is overwhelmingly probable that the process is already underway Either a player can position itself now with a licensing agreement during 2026 to secure the rights before competitors. The price tag will be lower because BP still takes some of the clinical risk towards H1 2027. Alternatively, they can await the outcome in 2027. If the data from the Copenhagen study then shows a clear reduction in bacterial load, the medical risk is eliminated – but then SoftOx will probably be subject to an aggressive bidding war between several of the largest pharmaceutical giants, and the price tag for an acquisition will reflect the enormous global market potential.
- ·11 t sittenSeems like the market doesn't care much about that type of news anymore. Saw the same in Circio yesterday and in Lifecare a few days ago. At Lifecare, it actually went up 10-15 % before it crashed down again.can one compare apples and bananas..? I Think not..that being said! then one should probably not put too much into one's expectations about what should happen with stocks, when there are "positive" news..we need more data. 📈 🚀
- ·12 t sitten · MuokattuPositive message regarding the confirmation that no significant side effects were registered. But no data regarding effect as this study was with healthy volunteers. Efficacy data for SIS-03 will come in H1 2027 and with convincing data here, the stock price can really take off and go 10x or more. So this is a somewhat long-term case where one must exercise some patience. Without knowing for sure, there might be some news from SIS-02 during the autumn that could affect the stock price.
- ·12 t sittenWe must wait until next year for further news on whether the medicine combats the disease to some extent. In that case, we will make a lot of money, if not, we will lose, some less, some more.For me, it's nothing special, they talked about it earlier, secondly, I believe there will be a big reaction after any positive news about the substance's effectiveness, but we have to wait for that.
- ·12 t sitten · MuokattuThe proof is now in place showing that this is going smoothly towards PoC. My goodness, how low priced we are now and what a buying opportunity. Today's news should send us above 0,25We can't get above 0.12 and you're talking about over 100% increase. If a whale sees potential here, it would probably have hoovered up all the shares at this level?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
2026 Q1 -tulosraportti
Äänite tulossa
2 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sittenClipped from TI: They sign confidentiality agreements (CDA/NDA) and gain access to "data rooms" When a potential partner shows interest (as we know from the Q1/Q3 reports that SoftOx is already in dialogue with), they sign a legally binding confidentiality agreement (Confidential Disclosure Agreement). Once it is signed, Big Pharma gains access to SoftOx's virtual "data room". Here they get access to extremely detailed information that is not publicly known: Raw data from previous safety studies, exact design of the CF study, animal studies (in vivo/in vitro), and patents in detail. With the recent appointment of Dr. Tore Duvold to the board – a man with extensive industrial experience from licensing agreements – it is overwhelmingly probable that the process is already underway Either a player can position itself now with a licensing agreement during 2026 to secure the rights before competitors. The price tag will be lower because BP still takes some of the clinical risk towards H1 2027. Alternatively, they can await the outcome in 2027. If the data from the Copenhagen study then shows a clear reduction in bacterial load, the medical risk is eliminated – but then SoftOx will probably be subject to an aggressive bidding war between several of the largest pharmaceutical giants, and the price tag for an acquisition will reflect the enormous global market potential.
- ·11 t sittenSeems like the market doesn't care much about that type of news anymore. Saw the same in Circio yesterday and in Lifecare a few days ago. At Lifecare, it actually went up 10-15 % before it crashed down again.can one compare apples and bananas..? I Think not..that being said! then one should probably not put too much into one's expectations about what should happen with stocks, when there are "positive" news..we need more data. 📈 🚀
- ·12 t sitten · MuokattuPositive message regarding the confirmation that no significant side effects were registered. But no data regarding effect as this study was with healthy volunteers. Efficacy data for SIS-03 will come in H1 2027 and with convincing data here, the stock price can really take off and go 10x or more. So this is a somewhat long-term case where one must exercise some patience. Without knowing for sure, there might be some news from SIS-02 during the autumn that could affect the stock price.
- ·12 t sittenWe must wait until next year for further news on whether the medicine combats the disease to some extent. In that case, we will make a lot of money, if not, we will lose, some less, some more.For me, it's nothing special, they talked about it earlier, secondly, I believe there will be a big reaction after any positive news about the substance's effectiveness, but we have to wait for that.
- ·12 t sitten · MuokattuThe proof is now in place showing that this is going smoothly towards PoC. My goodness, how low priced we are now and what a buying opportunity. Today's news should send us above 0,25We can't get above 0.12 and you're talking about over 100% increase. If a whale sees potential here, it would probably have hoovered up all the shares at this level?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt